Akèy › Kansè renn (Kasinom selil renn) › Pennsylvania › Pittsburgh
Etid klinik pou Kansè renn (Kasinom selil renn) nan Pittsburgh, PA
15 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Ap rekriteFaz 1
- Research Site, Pittsburgh
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Ap rekriteFaz 1/2
- UPMC Cancer Center/Hillman Cancer Center ( Site 5017), Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #32, Pittsburgh
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- UPMC-Saint Clair Hospital Cancer Center, Pittsburgh
- ak 2 plis
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Ap rekriteFaz 2
- Allegheny General Hospital, Pittsburgh
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- ak 14 plis
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Ap rekriteFaz 3
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- UPMC-Saint Clair Hospital Cancer Center, Pittsburgh
- ak 3 plis
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Pittsburgh
Autologous Dendritic Cell Vaccine in Kidney Cancer
Ap rekriteFaz 2
- UPMC Department of Urology, Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
Ap rekriteFaz 1
- UPMC- Hillman Cancer Center, Pittsburgh
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Ap rekriteFaz 3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- ak 9 plis
Etid Kansè renn (Kasinom selil renn) nan lòt vil
- Houston, TX35 etid
- New York City, NY27 etid
- Nashville, TN23 etid
- Dallas, TX23 etid
- St. Louis, MO23 etid
- Los Angeles, CA20 etid
- Boston, MA16 etid
- Baldwin Park, CA16 etid
- Philadelphia, PA15 etid
- Queens, NY15 etid
- Jacksonville, FL14 etid
- Cleveland, OH14 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè pwostat23 etid
- Kansè poumon23 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Akidan serebavaskilè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.